Low frequency of CDKN2 mutation in endometrial carcinomas

Related Experiment Video

Updated: Nov 9, 2026

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
09:48

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

S L Peiffer1, D Bartsch, A J Whelan

  • 1Department of Surgery, Washington University School of Medicine, St. Louis, Missouri 63110, USA.

Molecular Carcinogenesis
|August 1, 1995
PubMed

Insights

The CDKN2 gene, crucial for regulating cell division, showed alterations in some endometrial tumors. Researchers investigated its role in endometrial cancer development, finding mutations and deletions in a subset of samples.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The CDKN2 gene encodes the p16 protein, an inhibitor of cyclin D/cyclin-dependent kinase 4 complexes.
  • While CDKN2 mutations/deletions are common in cell lines, their frequency in primary tumors is lower.
  • Understanding CDKN2's role in endometrial cancer is important for tumorigenesis research.

Purpose of the Study:

  • To investigate the role of the CDKN2 gene in endometrial tumorigenesis.
  • To determine the frequency of CDKN2 alterations in endometrial carcinomas.

Main Methods:

  • Examined 34 endometrial tumor samples for loss of heterozygosity at chromosome 9p21 using flanking markers.
  • Assessed CDKN2 gene mutation frequency via single-strand conformation variant analysis and direct sequencing.

Main Results:

  • Loss of 9p21 sequences was observed in three out of 34 tumors.
  • Point mutations in CDKN2 were identified in two samples.
  • One sample exhibited both loss of 9p21 and a CDKN2 point mutation.

Conclusions:

  • CDKN2 alterations occur at a low frequency in primary endometrial carcinomas.
  • These findings suggest a potential, albeit infrequent, role for CDKN2 in endometrial cancer development.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...